Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials.

Antiviral research - 1 Jan 1996

Jacobsen H, Haenggi M, Ott M, Duncan I B, Andreoni M, Vella S, Mous J

Abstract excerpt

A genotypic analysis of the HIV-1 proteinase was performed on clinical specimen obtained from patients after different periods of Saquinavir (SQV) treatment. Proteinase genes of integrated proviral DNA from PBMC were isolated by PCR, cloned and individual sequences were obtained. Genotypic resistance was defined by the Gly48-->Val and Leu90-->Met exchanges. Frequencies and kinetics of resistance development will...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Microbial
Share to Genotype
Share to HIV-1

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Isoquinolines

Share to Mutation

Source

Identifiers

PMID: 8721556
DOI: 10.1016/0166-3542(95)00927-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials.PMID 8721556Read ↗

Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir.Semantic proximity Read ↗

Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy.Semantic proximity Read ↗

In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies.Semantic proximity Read ↗

Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir.Semantic proximity Read ↗

HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy.Semantic proximity Read ↗

Rational approaches to resistance: using saquinavir.Semantic proximity Read ↗

Protease inhibitors: drug resistance and cross resistance overview.Semantic proximity Read ↗

Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen.Semantic proximity Read ↗

Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.Semantic proximity Read ↗

Variant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitor.Semantic proximity Read ↗

Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.Semantic proximity Read ↗

Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.